Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes

Zacks Equity Research
·3-min read

On Jun 22, we issued an updated research report on Amedisys, Inc. AMED. The stock currently carries a Zacks Rank #3 (Hold).

This renowned home health and hospice services provider has outperformed its industry over the past six months. The stock has gained 22.7% against 4.1% decline of the industry in the said time frame.

The company noted that the COVID-19-led economic mayhem has had a mixed impact on the company’s business. Before the second week of March, Amedisys witnessed a decline in referral volumes and an increase in MIS visits. Beginning the second week of March, the company started to see a drop in MIS visits while witnessing steady recovery in referral volumes in all lines of businesses.

In hospice, while referrals hit a low, admission volumes have significantly improved. The company has already started to see signs of progress in episodes since March. Although the impact of COVID-19 ultimately led to increased lupus and lost building periods in this population (the full impact is expected in the second quarter), the company is confident that it can achieve its target improvements to mitigate the impact of behavioral assumptions once COVID-19 subsides.

Amedisys, Inc. Price

Amedisys, Inc. Price
Amedisys, Inc. Price

Amedisys, Inc. price | Amedisys, Inc. Quote

Meanwhile, we note that, Amedisys is currently exploring opportunities in Home Health and Hospice segments. Amedisys has been benefiting from the recent acquisitions of hospice care providers — Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice (CCH).

However, elevated operating expenses and a declining gross margin continue to raise concerns. Further, an intensely competitive landscape and reimbursement woes weigh on the home health and hospice industry.

Key Picks

A few top-ranked stocks from the broader medical space are Quest Diagnostics Incorporated DGX, Hologic, Inc. HOLX and QIAGEN N.V. QGEN.

Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hologic’s long-term earnings growth rate is estimated at 7%. The company presently has a Zacks Rank #2.

QIAGEN’s long-term earnings growth rate is estimated at 12.2%. It currently sports a Zacks Rank #1.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Amedisys, Inc. (AMED) : Free Stock Analysis Report
 
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
 
Hologic, Inc. (HOLX) : Free Stock Analysis Report
 
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research